440 filings
Page 4 of 22
6-K
CLLS
Cellectis
7 Feb 23
Current report (foreign)
6:28am
424B5
CLLS
Cellectis
3 Feb 23
Prospectus supplement for primary offering
4:01pm
6-K
CLLS
Cellectis
3 Feb 23
Cellectis Supplements the Announcement of the Pricing of Follow-On Offering with Allocation of Share Capital Information
10:10am
6-K
CLLS
Cellectis
3 Feb 23
Cellectis Announces Pricing of Follow-On Offering
6:50am
6-K
CLLS
Cellectis
2 Feb 23
Cellectis Announces Launch of Follow-On Offering
4:12pm
424B5
CLLS
Cellectis
2 Feb 23
Prospectus supplement for primary offering
4:02pm
6-K
CLLS
Cellectis
20 Jan 23
Cellectis Amends $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics
4:36pm
SC 13G/A
CLLS
Cellectis
18 Jan 23
Cellectis / BAILLIE GIFFORD & CO ownership change
10:03am
SC 13D/A
CLLS
Cellectis
17 Jan 23
Calyxt / Cellectis ownership change
4:08pm
6-K
CLLS
Cellectis
17 Jan 23
Current report (foreign)
4:05pm
6-K
CLLS
Cellectis
17 Jan 23
Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement
7:16am
FWP
CLLS
Cellectis
4 Jan 23
Free writing prospectus
5:16pm
6-K
CLLS
Cellectis
4 Jan 23
Current report (foreign)
5:13pm
6-K
CLLS
Cellectis
4 Jan 23
Current report (foreign)
5:04pm
424B5
CLLS
Cellectis
4 Jan 23
Prospectus supplement for primary offering
4:59pm
6-K
CLLS
Cellectis
4 Jan 23
Current report (foreign)
4:24pm
6-K
CLLS
Cellectis
4 Jan 23
Current report (foreign)
4:21pm
6-K
CLLS
Cellectis
29 Dec 22
Current report (foreign)
4:42pm
6-K
CLLS
Cellectis
28 Dec 22
Cellectis secures a €40 million credit facility from the European Investment Bank to support its Research, Development and Innovation activities
4:37pm
6-K
CLLS
Cellectis
22 Dec 22
Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL
4:31pm